

PATENT APPLICATION TRANSMITTAL LETTER

Docket Number: BAK-073.01

Patent Group
Foley, Hoag & Eliot LLP
One Post Office Square
Boston, MA 02109-2170

Assistant Commissioner for Patents:

Transmitted herewith for filing under 35 U.S.C. 111 and 37 CFR 1.53 is the patent application of

Chirag B. Shah and Laurel L. Wolfgang
entitled THROMBORESISTANT COATING

Enclosed are:

(X) 45 pages of written description, claims and abstract.
() sheets of drawings.
(X) executed declaration and power of attorney
() executed verified statement to establish small entity status under 37 CFR 1.9 and 1.27.
() other: _____

jc549 U.S. PTO
09/138464
08/21/98**CLAIMS AS FILED**

	NUMBER FILED	NUMBER EXTRA	RATE	FEE
BASIC FEE (37 CFR 1.16(a))			\$790	\$790
TOTAL CLAIMS (37 CFR 1.16(c))	59	-20 = 39	x \$22	858
INDEPENDENT CLAIMS (37 CFR 1.16(b))	5	-3 = 2	x \$82	164
MULTIPLE DEPENDENT CLAIM PRESENT		(37 CFR 1.16(d))	\$270	
* NUMBER EXTRA MUST BE ZERO OR LARGER			TOTAL	\$1,812
	If applicant has small entity status under 37 CFR 1.9 and 1.27 then divide total fee by 2, and enter amount here.			SMALL ENTITY


(X) A check in the amount of \$ 1,812.00 to cover the filing fee is enclosed.

(x) The Commissioner is hereby authorized to charge and credit Deposit Account No. **06-1448** as described below. I have enclosed a duplicate copy of this sheet.

() Charge the amount of \$ _____ as filing fee.
(x) Credit any overpayment.
(x) Charge any additional filing fees required under 37 CFR 1.16 and 1.17.
() Charge the issue fee set in 37 CFR 1.18 at the mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b).

Certificate of Express Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, postage prepaid, "Post Office to Addressee", in an envelope addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on this date of August 21, 1998.



Ariel Collazo
Express Mail Label:EL 046 502 600 US
Date of Deposit: August 21, 1998



Charles H. Cella
Reg. No. 38,099

THROMBORESISTANT COATING

Background of The Invention

1. Field of the Invention

This application relates to the field of medical devices and more particularly to the
5 field of coatings for medical devices.

2. Description of Related Art

Arteriosclerosis is a condition that detrimentally affects many individuals. Untreated, arteriosclerosis may lead to severe consequences, including heart damage, heart attack and death. Known treatments for arteriosclerosis have had limited success.

10 Transluminal balloon angioplasty, wherein a balloon is inserted via a catheter into the artery of the patient and expanded, thereby simultaneously expanding the partially closed artery to a more open state, is a well-known treatment for arteriosclerosis, but long-term benefits of balloon angioplasty are limited by the problems of occlusion and restenosis, which result in re-closure of the artery.

15 A variety of intravascular stents and prostheses have been developed to support diseased arteries and thereby inhibit arterial closure after angioplasty. In particular, expandable intraluminal stents have been developed in which a catheter is used to implant a stent into the artery of the patient in a minimally invasive manner.

20 Like other foreign bodies placed into arteries, stents can result in coagulation or thrombosis in the intravascular environment. Thrombosis can inhibit blood flow

through the stent, diminishing its effectiveness, or can cause clotting, which can threaten the life of the patient. Accordingly, methods of reducing thrombotic activity have been sought to reduce the negative side effects caused by certain stents.

A number of coatings have been developed for medical devices that are intended to 5 promote compatibility between a particular medical device and the environment in which the medical device resides. Some of these coatings, known as thromboresistant coatings, are intended to reduce the thrombosis often associated with insertion of a foreign object, such as a medical device, into the interior of the body.

Heparin, or heparinic acid, arteven, or leparan, is a glycosaminoglycan with well-known anticoagulant activity. Heparin is biosynthesized and stored in mast cells of 10 various animal tissues, particularly the liver, lung and gut. Heparin is known to have antithrombotic activity as a result of its ability to bind and activate antithrombin III, a plasma protein which inhibits several enzymes in the coagulation cascade. It has been hoped that heparin coatings, by inhibiting thrombogenesis, can improve the therapeutic 15 outcomes derived from intra-vascular medical devices, such as stents.

However, known heparin coatings are subject to a number of defects, including 20 incompatibility with the organism and/or microscopic features of the surface to be coated, excessive thickness, difficulty in application, and insufficient durability. For example, several known coatings are based upon simultaneous coulombic interactions between heparin and tri(dodecyl)methylammonium chloride, which is also referred to herein as

heparin-TDMAC, and hydrophobic interactions between the quaternary ammonium ion of heparin-TDMAC and the surface of the device. Due to the relative weakness of hydrophobic interactions, such coatings typically leach away from the substrate to which they are applied within a few hours; coatings of this type, therefore, are not generally durable enough to provide beneficial therapeutic results.

5

Other known coatings comprise silanes having a pendent amino or vinyl functionality. In the fabrication of these coatings, a base layer of silane is applied initially to the surface, followed by the application to the base layer of a second layer comprising antithrombogenic biomolecules, such as heparin. It is necessary that the pendent groups of the base layer of silane be both complementary and accessible to groups on heparin. In some such coatings, a silane with terminal amino functionality is applied to a substrate to form a first layer, followed by application of heparin in solution to form the second layer. In certain examples of this strategy, the amino functionality of the silane base layer reacts with an aldehyde-containing heparin derivative to form a Schiff base and thereby covalently attach the biomolecule to the base layer. In another group of coatings of this general class, a base layer comprising a silane with a vinyl functional group is applied to a surface, followed by covalent attachment, via free radical chemistry, of a heparin-containing derivative to the base layer.

10

15

20

Some of the known coatings have been found lacking in bioeffectiveness and stability. Modifications made in these coatings utilize additional coatings of polymeric matrices comprising reactive functionalities. The multi-step process required to fabricate

the polymeric matrices necessary in these approaches increases the thickness of the resulting coatings. Thick coatings present a number of difficulties. First, thick coatings increase the profile of the medical device in the intravascular environment. A stent with a thick profile, for example, can reduce blood flow, thereby undermining the therapeutic benefit of the stent. A thick coating may also render the coating itself more vulnerable to pitting, chipping, cracking, or peeling when the stent is flexed, crimped, expanded, or subjected to intravascular forces. Any of the foregoing results of excessively thick coatings may reduce the antithrombogenic characteristics of the stent. Moreover, the likelihood of pitting is hypothesized to be greater in thick coatings, and pits in a coating may increase the susceptibility to galvanic corrosion of the underlying surface. Because their fabrication requires additional steps, coatings comprising multiple layers may also be more difficult and expensive to manufacture.

Accordingly, a need exists for a thromboresistant coating that is thin, durable, and biocompatible, and that may be applied in a single coating.

15 Summary of the Invention

Coatings are provided herein in which biopolymers may be covalently linked to a substrate. Such biopolymers include those that impart thromboresistance and/or biocompatibility to the substrate, which may be a medical device. Coatings disclosed herein include those that permit coating of a medical device in a single layer, including coatings that permit applying the single layer without a primer. It should be understood 20 that it may be advantageous in some circumstances to apply double layers of the coatings,

such as to cover an area of a medical device that is used to hold the device while a first layer is applied. Thus, single, double and multiple layers of coatings are encompassed by the coatings disclosed herein.

5 The coatings disclosed herein include those that use an adduct of heparin molecules to provide thromboresistance. The heparin molecules may comprise heparin-tri(dodecyl)methylammonium chloride complex. Uses of the term "heparin" herein should be understood to include heparin, as well as any other heparin complex, including heparin-tri(dodecyl)methylammonium chloride complex.

10 The coatings described herein further include those that use a silane to covalently link a biopolymer to a substrate. The coatings include those derived from silanes comprising isocyanate functionality.

The disclosed coatings include those that can be applied without a base or primer layer.

15 Coatings are also included that provide a thin and durable coating wherein the thickness of said coating can be controlled by application of single or multiple layers.

Coatings are provided wherein thromboresistance activity can be modified by choice of appropriate amounts of heparin-TDMAC complex and silane.

Thin, durable coatings are provided having controllable bioactivity.

Single or multi-layer coatings disclosed herein are designed to impart thromboresistance and/or biocompatibility to a medical device. In one embodiment, the coating provides for covalent linking of heparin to the surface of the medical device.

5 One coating formulation of the present invention initially consists of heparin-TDMAC complex, organic solvent and silane. Wetting agents may be added to this formulation. A silane is chosen that has an organic chain between isocyanate and silane functionalities. The isocyanate functionality reacts with an amino or hydroxyl group on the heparin molecule. After the reaction, the formulation contains covalent adducts of heparin and silane, in addition to organic solvent and other additives. Unreacted silane or 10 heparin-TDMAC complex may be present in the formulation, depending on the relative amounts of the reagents utilized.

15 Once the coating formulation is applied to a device, the silane end group of the adduct mentioned above adheres to the substrate surface, and a network, or film, containing heparin-TDMAC complexes is created on the surface of a substrate. Heparin molecules in the heparin-TDMAC complex are known to have anticoagulant properties. When exposed to blood, heparin molecules inactivate certain coagulation factors, thus preventing thrombus formation.

The direct adherence of the silane end group to the substrate means that the

coating may be applied to a wide range of medical device materials without the use of a base/primer layer. The covalent bond between the surface and the silicon of the silane comprising the heparin-TDMAC complex provides superior durability compared to known coatings.

5 The coating can be applied by dip coating, spray coating, painting or wiping. Dip coating is a preferred mode.

10 The coating can be thin and durable. The coating thickness can be controlled in a number of ways, e.g., by the application of single or multiple layers. Since the coating process described herein may be a one-step process, coating thickness is not increased as a result of the need to apply multiple layers, as in certain known coating methods.

15 The bioeffectiveness of the coatings can be controlled by selecting appropriate amounts of reactants. In particular, the thromboresistance activity of the coating can be controlled by modifying the amount of heparin-TDMAC complex in the coating.

Detailed Description of the Preferred Embodiments

15 Single or multi-layer coatings are provided herein that are designed to impart thromboresistance and/or biocompatibility to a medical device. In an embodiment of the invention, the coating provides for the covalent linking of heparin molecules to a substrate.

A heparin molecule is understood to contain a specific art-recognized

pentasaccharide unit that displays antithrombogenic qualities. Covalent linkage of a heparin molecule to a surface is understood to affect at least one, but not all, of the hydroxyl and amino moieties comprised by that molecule; the covalently linked heparin, therefore, presents a thromboresistant surface to the environment surrounding the coated substrate. Different methods and formulations for covalently linking heparin to the surface 5 may affect different sites on the heparin molecules, so that different formulations will provide different levels of anti-thrombogenicity.

One coating formulation of the present invention initially consists of heparin-TDMAC complex, organic solvent and a silane. Other biopolymers may be used in place 10 of or in addition to heparin-TDMAC complex, and such biopolymers may be covalently linked to a substrate according to the present invention. Such biopolymers may be those that provide thromboresistance, or those that have other desired bioactivity.

The silane provided may have functionality capable of reacting with a nucleophilic 15 group, e.g., a hydroxyl or amino group. In particular, the silane may comprise isocyanate, isothiocyanate, ester, anhydride, acyl halide, alkyl halide, epoxide, or aziridine functionality. In certain embodiments described herein, the silane comprises isocyanate functionality.

The silane comprising isocyanate functionality may be linked covalently to any 20 biopolymer that provides anti-thrombogenicity. The selected biopolymer may be selected from a group of heparin complexes, including heparin-tridodecylmethylammonium

chloride, heparin-benzalkonium chloride, heparin-steralkonium chloride, heparin-poly-*N*-5
vinyl-pyrrolidone, heparin-lecithin, heparin-didodecyldimethyl ammonium bromide, heparin-pyridinium chloride, and heparin-synthetic glycolipid complexes. The selected
biopolymer may also be another biopolymer that has hydroxyl or amine functional groups
that can react with the isocyanate functionality of the silane.

The selected biopolymer is preferably capable of dissolving in an organic solvent, as opposed to biopolymers that dissolve only in water. Solubility in organic solvents confers a number of advantages, e.g., elimination of water-mediated decomposition of the isocyanate-containing silane.

10 In one preferred embodiment, the selected biopolymer is heparin-tri(dodecyl)methylammonium chloride complex.

Wetting agents and other additives may be added to the coatings described herein, to improve the adherence to the substrate, to improve the ease of adding the coatings to a substrate, or for other purposes. A variety of organic solvents may be used, including 15 tetrahydrofuran (THF). Additives may include surface active agents, such as Triton.

The selected silanes may have an organic chain between the isocyanate functionality, which covalently links to the heparin molecule, and an end group that is capable of linking to a substrate surface. The end group may link to pendant oxide groups on the substrate surface; in some cases, the pendant oxide groups may be obtained by

oxidation of the substrate.

The bioactivity, including thromboresistance, of the disclosed coatings may be selectively modified by controlling the amounts of heparin-tridodecylmethylammonium chloride complex, silane comprising isocyanate functionality, and organic solvent, as well as other constituents, to provide the desired thromboresistance. In an embodiment of the 5 coatings, the concentration of the silane in the formulation is between about one-half percent and about four percent. In an embodiment, the concentration of heparin-tridodecylmethylammonium chloride in the formulation is between about one-tenth percent and about four percent. One preferred coating is a solution with a formulation of 10 silane of about five-tenths percent and a formulation of the heparin-tridodecylmethylammonium chloride complex of about two-tenths percent. In one such preferred solution, the organic solvent is tetrahydrofuran.

Heparin molecules, including those in heparin-TDMAC complex are known to have anticoagulant properties. When exposed to blood, structural elements of heparin 15 molecules inactivate certain coagulation factors, thus preventing thrombus formation.

The coatings described herein may be applied in a single layer. The layer can be formed by reacting silane having isocyanate functionality with a heparin in an organic solvent to form a silane-heparin complex, which can be applied directly to a substrate, such as a metal substrate, in a single-layer coating that can be applied without a primer. 20 The single layer can thus be made sufficiently thin to minimize the problems of peeling,

cracking, and other problems that characterize some thicker coatings that require multiple layers, primers, or polymeric matrices for binding to the substrate. Thus, the layers may perform better under the mechanical crimping or expansion of a medical device, such as a stent, to which they are applied, and may perform better in the intravascular environment.

5

The silane end groups of the monomer that yield the coatings react with oxides or hydroxyl groups on the surface of stainless steel. The stainless steel surface may be oxidized or cleaned and pre-treated, such as with sodium hydroxide, to increase the number of appropriate sites for linking the silane end groups.

REDACTED

10

To improve hydrolytic stability, non-functional silanes can be added to the formulations disclosed herein. Other silanes may be used to link to substrates, such as trihalosilanes, and silanes having methoxy and ethoxy groups. Silanes having triethoxy, trialkoxy, trichloro, and other groups may be provided to yield the covalent linkages present in the coatings disclosed herein. The non-functional silanes may be selected from the group consisting of chain alkyltrialkoxysilanes and phenyltrialkoxysilanes.

15

In an embodiment, the amount of functional silane is preferably selected to provide substantially complete coverage of the substrate surface; that is, it may be desirable to have the single layer cover all of the surface that would otherwise be exposed to the environment in which the substrate will be placed.

20

The adherence of the silane end group to the substrate means that the coating may

be applied to a wide range of medical device materials without the use of base/primer layer. The covalent bond between the heparin-TDMAC complex and the substrate provides a thin and durable coating. The coating's thickness can be controlled, e.g. by choice of the length of the chain connecting the silane and isocyanate functionalities.

5 The bioeffectiveness and/or bioactivity of the thromboresistant coating can be controlled by selecting appropriate amounts of reactants. In particular, the thromboresistance activity of the coating can be modified by modifying the amounts of heparin-TDMAC complex and silane in the coating.

10 Single layers have further advantages in that problems may arise in the extra steps required for the deposition of multiple layers. For example, dust or other particulates may appear between coatings in two-step processes. Also, application of a second layer may tend to reduce reactivity of the first layer in an unpredictable way.

15 Coatings of the present invention may be applied to medical devices that are placed in the body of a human, or that remain outside the body. Coated medical devices that are placed in the human body may include stents, catheters, prostheses and other devices. Coated medical devices that remain outside the human body may include tubing for the transport of blood and vessels for the storage of blood. Substrates or medical devices on which the coatings described herein may be applied can include a wide variety of materials, including stainless steel, nitinol, tantalum, glass, ceramics, nickel, titanium, aluminum and other materials suitable for manufacture of a medical device.

The coatings disclosed herein may further include a film-forming agent for the coating. The film-forming agents could slow any leaching of the biopolymer from the coating. The film forming-agent could be added in a second layer, or dissolved simultaneously with the silane and the biopolymer. Appropriate film-forming agents could 5 include cellulose esters, polydialkyl siloxanes, polyurethanes, acrylic polymers or elastomers, as well as biodegradable polymers such as polylactic acid (PLA), polyglycolic acid (PGA), copolymers of PLA and PGA, known as PLGA, poly(*e*-caprolactone), and the like.

To create coatings of the present invention, the silanes and heparin complex are 10 dissolved in a solvent, which may be an organic solvent. The solutions preferably should be substantially anhydrous, because water tends to react with isocyanate groups of the silane molecule. The water may be added after mixing the silane-isocyanate with heparin. In certain embodiments, the silane and heparin are combined in solution, the resulting 15 solution is aged for about one day, the pH is adjusted with a weak acid, and then water is added to hydrolyze silane. The pH of the solution may be adjusted with aqueous acetic acid. Instead of adding water, it is possible to hydrolyze the silane groups by exposure to moist atmospheric conditions. It is desirable to mix the silane and heparin complex in a manner so as to include a slight excess of heparin molecules, so that all of the isocyanate is reacted, preventing adverse reactions between the isocyanate and any water. Moreover, it 20 is desirable to have a single heparin react with each silane isocyanate functional group; this goal is most easily accomplished by starting with an excess of heparin.

Based on experimental results, it was found that, in certain embodiments, solutions of about two-tenths percent heparin complex and about five-tenths percent silane provided effective coatings. However, coatings in a fairly wide range may be effective. Thus, coatings are likely to have some effectiveness in cases in which heparin complex is present in concentrations ranging from about one-tenth of a percent to about twenty percent.

5 Coatings with heparin in concentrations of less than ten percent may be preferable in some formulations. Coatings with heparin in concentrations of less than five percent may be preferable in other formulations. Coatings may be expected to be effective in formulations in which silane is present in a wider range of concentrations as well, including concentrations ranging from about one-tenth of a percent silane to about twenty percent silane.

10 The thromboresistant characteristics of heparin coatings can be assessed qualitatively and quantitatively, so that methods can be developed that provide uniform coating with a desired amount of bioactivity. Successfully heparinized surfaces give a purple stain when exposed to toluidine blue. After coating, the surface is exposed to a saline solution for a number of days or weeks, and thromboresistance activity is measured as a function of time. Stents and coupons coated as disclosed herein were shown 15 experimentally to display long-lived thromboresistant properties; bioactivity persisted for periods on the order of months, and it will probably endure much longer.

20 The heparin activity of a sample may be quantified based on its ability to inactivate thrombin. To quantify heparin activity in experimental assays, heparin may be first mixed

with human antithrombin III, which binds to create a complex. The heparin-antithrombin III complex can then be mixed with thrombin to produce a ternary complex comprising heparin, thrombin, and antithrombin. The heparin then departs this complex and is free to react again with available antithrombin and thrombin to create additional thrombin-antithrombin complexes. Thus, heparin acts as a catalyst for the antithrombin-mediated deactivation of thrombin. The reaction of the active thrombin still left in the solution with a substrate produces a proportional amount of p-nitro aniline exhibiting color. Thus, an assay may be conducted for a spectrophotometric analysis of color, to determine the amount of thrombin left in solution. The more thrombin left in solution, the lower the bioactivity of the heparin. A low level of thrombin in solution indicates a high degree of catalysis of the thrombin-antithrombin reaction, which indicates a high level of thromboresistance provided by the heparin. A baseline comparison for the assay is the very slow reaction of thrombin-antithrombin in the absence of heparin. The results of the assay can be quantified using spectrophotometry. The assay mimics the reactions that occur in the human bloodstream, where thrombin and anti-thrombin circulate at all times. The reaction between antithrombin and thrombin in the body, which is catalyzed by the heparin of the coatings of the present invention, helps suppress the coagulation that results from thrombogenesis on a medical device.

Various methods of making coatings of the present invention are possible, and examples of such methods and certain resulting coatings are as follows. Such methods and coatings are disclosed by way of example, and are not intended to be limiting, as other examples may be readily envisioned by one of ordinary skill in the art. The following

examples include methods of providing coatings of the present invention in a single layer, without the need for a primer layer, as well as methods of controlling the bioactivity of the resulting coating. In some instances, experimental results are provided showing sustained bioactivity for the particular coating.

5 Coatings can be applied in a wide variety of conventional ways, including painting, spraying, dipping, vapor deposition, epitaxial growth and other methods known to those of ordinary skill in the art.

To test coatings disclosed herein, infrared scans were performed to demonstrate changes in the isocyanate functionality, through observation of the isocyanate peak (NCO, 2260 or 2270 cm⁻¹) over time. Isocyanatosilane was formulated with different components, including heparin-tridodecylmethylammonium chloride complex(Heparin-TDMAC complex), tetrahydrofuran (“THF”) and Triton (an optional, surface active agent) in solution to determine whether the intensity of the isocyanate peak changed over time. Table 1 shows the observation of the isocyanate functionality for different solution constituents:

TABLE 1

<u>Solution</u>	<u>Observation</u>
1) Silane + THF	No change in peak with time
2) Silane + THF + TDMAC	No change in peak with time
3) Silane + THF + Triton	No change in peak with time

4) Silane + THF + Heparin-TDMAC complex Peak disappears with time depending on the concentration of silane and heparin-TDMAC complex

5 The observation that the isocyanate peak disappears with time in the solution that includes silane, THF and Heparin-TDMAC complex suggests that a reaction occurs between functional groups on heparin and the isocyanate group of silane.


In embodiments of the present invention, the coating formulation contains the following constituents, which may vary in concentrations in different embodiments:

10 Heparin-TDMAC complex, an organic solvent, such as THF, a silane, such as 3-isocyanatopropyl triethoxysilane ($\text{OCN}-(\text{CH}_2)_3-\text{Si}(\text{OEt})_3$), and Triton (x-100). In a first embodiment, a solution of these constituents was mixed and allowed to sit in order to permit a reaction to occur. Allowing the solution to sit for one day allowed the reaction to occur, but shorter reaction times may well be effective. Before coating the substrate with the solution, the pH was adjusted. Solutions of the above constituents were adjusted to a pH between 4.5 and 5.5 using a solution of acetic acid and water. After adjusting pH, it is desirable to wait for a period of time, such as fifteen minutes, before applying the coating. Once the coating was applied, it was dried in air and cured in an oven. In particular, coatings of the above constituents were dried in air for about twenty minutes and then cured in an oven at eighty-five degrees Celsius for about one hour.


Coatings, derived from the above-described solutions, on coupons and stents were tested in various ways. First, as a qualitative test, coated coupons and stents were dipped

in toluidine blue solution and then were screened for the presence of a purple stain. As mentioned above, the presence of a purple stain in this assay indicates the presence of heparin in the sample being assayed. Additionally, the intensity of the purple stain observed in this assay is proportional to the amount of heparin in the sample. Therefore, a comparison of the intensities of the purple stains produced in this assay by a set of samples allows an assignment of the relative amounts of heparin comprised by the coatings of those samples.


As a quantitative test for heparin activity, a heparin activity assay was conducted according to a conventional thrombin inhibition assay technique. The heparin assay permitted determination of the ability of the heparin coating to deactivate thrombin and thus to provide thromboresistance. The purpose of the protocol was to assay for heparin activity based on thrombin inhibition. A number of different reactions are understood to take place in order to determine heparin activity. In the first reaction:



Heparin reacts with Human Antithrombin III ("ATIII") to yield a Heparin-Antithrombin III complex. In the second reaction:



the Heparin-Antithrombin complex reacts with Thrombin to yield a Heparin-Antithrombin-Thrombin complex. In the third reaction:



the amount of the thrombin was measured. As a result, the size of the p-nitroaniline peak measured at 405 nm is inversely proportional to the amount of heparin present.

Exemplification

The invention now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit 5 the invention.

General Procedures

In the following examples, heparin activity on coated coupons or stents was measured after exposing the coated object to a continuous flow of saline at thirty-seven degrees Celsius for a selected time period. Stainless steel coupons and stents were 10 cleaned before coating. The coupons or stents were cleaned with several organic solvents, such as hexane and isopropanol, followed by rinsing with distilled water. The cleaning procedure was carried out in an ultrasonic bath for fifteen minutes. After this procedure, the coupons or stents were placed in sodium hydroxide solution (1.0 N) for fifteen minutes and then washed thoroughly with distilled water. Samples were air dried before coating.

15 It should be noted that thrombin inhibition assay techniques are notoriously subject to significant sample error; accordingly, it is not unusual to obtain variable experimental results for a given sample. The examples below identify results for multiple samples under a variety of conditions and thus indicate in the aggregate that the coatings described herein are likely to provide therapeutic levels of thromboresistance. However, results from any 20 single formulation were found to vary somewhat depending on particular sample conditions. In cases where more than one set of data is provided for a given sample, the

individual data sets reflect measurements taken at distinct positions on that sample; the data sets in these cases, therefore, do not necessarily reflect a lack of precision in the measurements.

Example 1:

5 Stainless steel coupons were coated with a formulation of 1% heparin-TDMAC complex, 2% silane and 97% THF. The coupons were dipped once in the formulation, with a dwell time of five seconds at a coating speed of 10 in/min, to give a single layer of coating. Results are set forth in Table 2.

Table 2

Sample	Activity, mU/cm ²	
	Unwashed	7 days wash
97-080-90C	<10	<10
97-080-90C	<15	<10
97-080-90D	<15	<5
97-080-90D	<15	<5

10 15 The coating showed toluidine blue stain before and after washing with water. The coating showed heparin activity after one week of exposure to saline.

Example 2:

 Stainless steel coupons were dipped once, at coating speeds of 10 in/min and 42 in/min and for a dwell time of five seconds, and resulting in single layer coatings of 20 different thickness, in the following formulations: 1) 7% heparin-TDMAC complex, 2% silane and 91% THF and a small amount of Triton; and 2) 2% heparin-TDMAC complex, 2% silane and 96% THF and a small amount of Triton. Sample pieces were cut from

coupons and were either washed or not washed before being measured under the indicated conditions after the indicated amounts of time. Results are set forth in Table 3:

Table 3

Sample	Activity, mU/cm ²				
	1 day unwashed	2 days unwashed	1 day wash	2 days wash	7 days wash
97-100-9A	<50	<75	<15	<25	<25
97-100-9A	<50	<75	<15	<25	<25
97-100-9B	<50	<75	<25	<50	<50
97-100-9B	<75	<75	<15	<50	<10

A toluidine blue stain was present before and after washing, and the coupons showed heparin activity after seven days of washing. Combined with Example 1, the results showed that heparin activity can be varied using different coating formulations and coating processes.

Example 3:

Stainless steel coupons were dipped once, at speeds of 10 in/min and 42 in/min, and for dwell times of five seconds, two minutes and fifteen minutes, and resulting in coatings of different thickness, in the following formulations: 1) 7% heparin-TDMAC complex, 2% silane and 91% THF and a small amount of Triton; and 2) 2% heparin-TDMAC complex, 2% silane and 96% THF and a small amount of Triton. Results are shown in Table 4.

Table 4

Sample	Activity, mU/cm ²		
	1 day unwashed	1 day wash	7 days wash
97-100-15A	<150	<10	<5
97-100-15A	<100	<10	<10
97-100-15B	<50	<10	<25
97-100-15B	<25	<1	<25
97-100-15C	<75	<25	
97-100-15C	<100	<50	
97-100-15D	<150	<50	
97-100-15D	<150	<50	
97-100-15E	<150	<10	<10
97-100-15E	<150	<25	<25
97-100-15F	<150	<10	<25
97-100-15F	<200	<25	<25
97-100-15G	<150	<25	
97-100-15G	<150	<25	
97-100-15H	<150	<50	
97-100-15H	<150	<50	
97-100-15I	<200	<100	<50
97-100-15I	<200	<75	<75
97-100-15J	<200	<100	
97-100-15J	<250	<100	

Seven day results were for certain pieces measured at the one day point and then placed back into a flusher for additional days of washing. Toluidine blue stains were present before and after wash, with shades differing with thickness. Heparin activity was present after seven days of washing. In combination with Examples 1 and 2, this example demonstrated that heparin activity can be varied using different coating formulation and coating processes.

Example 4:

5

heparin-TDMAC complex, 2% silane, 96% THF and a small amount of Triton. Certain coupons were dipped into toluidine blue solution and rubbed under water. The coupons were then redipped in toluidine blue and checked for the presence of a stain. Results are shown in Table 5.

Table 5

Sample	Appearance	Toluidine blue stain before rub test	Toluidine blue stain after rub test
97-100-30A	Good coating, thin	Uniform, light	Uniform, light
97-100-30B	Good coating, thin	Uniform, light	Uniform, light
97-100-30C	Good coating, thin	Uniform, light	Uniform, light
97-100-30D	Good coating, thin	Uniform, light	Uniform, light
97-100-30E	Good coating, thin	Uniform, light	Uniform, light
97-100-30F	Good coating, thin	Dark gritty stain	Uniform, light, some peeling

10

15

A qualitative assessment of the effect of different solvents on coating was also performed, by dipping a coated sample in solvent for 60 seconds and then washing it with water and staining it with toluidine blue. Results are shown in Table 6.

5 **Table 6**

Sample	Solvent				
	IPA	Toluene	Hot water (high pressure flow)	Hot water (high pressure flow)	Acetone
97-100-30G	Good purple stain	No stain	Light stain	Light stain	Good stain

10 Heparin activity is displayed in Table 7.

15 **Table 7**

Sample	Activity, mU/cm ²	
	1 day unwashed	1 days wash
97-100-30A	<150	<25
97-100-30A	<150	<25
97-100-30B	<75	-
97-100-30B	<75	-
97-100-30C	<50	-
97-100-30C	<50	-
97-100-30D	<50	-
97-100-30D	<50	-
97-100-30E	<10	-
97-100-30E	<25	-
97-100-30F	<10	-
97-100-30F	<25	-
97-100-30G	<25	<25
97-100-30G	<25	<25

20 This example indicated that coating thickness may be dependent on dwell time, that rubbing does not remove the coating as indicated by stains after rubbing, that washing with various solvents has a different effect on coating durability, and that heparin activity was present after washing. The example provided further evidence that heparin activity can be varied using different coating processes.

25 *Example 5:*

Stainless steel coupons were dipped once, at speeds of 10 in/min, and for dwell times of two and fifteen minutes, in the following formulations: 1) 2% heparin-TDMAC complex,

4% silane and 94% THF and a small amount of Triton; 2) 2% heparin-TDMAC complex, 8% silane and 90% THF and a small amount of Triton; 3) 4% heparin-TDMAC complex, 4% silane and 92% THF and a small amount of Triton; and 4) Diluted 4% heparin-TDMAC complex, 4% silane and 92% THF and a small amount of Triton.

5 Coated coupons were dipped in toluidine blue solution and rubbed with fingers under
water, then redipped in toluidine blue and checked for stains. Results are displayed in Table
8

Table 8

Sample	Appearance	Toluidine blue stain before rub test	Toluidine blue stain after rub test
97-100-36A (2 min)	Good coating	Uniform stain	Uniform
97-100-36A(15 min)	Good coating	Uniform stain	Uniform
97-100-36B(2 min)	Good coating	Uniform stain	Uniform
97-100-36B(15 min)	Good coating	Uniform stain	Uniform
97-100-36C (15 min)	Good coating	Very thick, gritty	Uniform, some peeling
97-100-36C (15 min)	Good coating	Very thick, gritty	Uniform, some peeling
97-100-36D (2 min)	Good coating	Uniform stain	Uniform
97-100-36D (15min)	Good coating	Uniform stain	Uniform, some peeling

Heparin activity for this example is displayed in Table 9.

Table 9

Sample	Coating (%/% heptdmac/silane)	Activity, mU/cm ²				
		1 day unwashed	30 days unwashed	1 day wash	30 days wash	87 days wash
97-100-36A(2 min dwell)	2.0/4.0	<150, <125	<50	<25, <25	<5	<1, <1
97-100-36B(2 min)	4.0/8.0	<25, <25	<25	<25, <25	<5	<1, <1
97-100-36C (2 min)	4.0/4.0	<175, <150	<150	<50, <25	<5	<1, <1
97-100-36C (2 min)	Diluted, 4.0/4.0	<50, <100	<150	<25, <25	<5	0, <1

This example demonstrated that for thin coatings thickness is not strongly dependent on dwell time. Also, rubbing does not remove the coating, as indicated by stains after rubbing. Long term durability of the coating is evident from heparin activity results. Again, heparin activity can be varied using different coating formulation and processes.

Example 6:

Stainless steel coupons were dipped once, at speeds of 10 in/min and for a dwell time of two minutes, in the following formulation: 2% heparin-TDMAC complex, 2% silane and 96% THF and a small amount of Triton. The coupons were then either left unsterilized, or sterilized with ethylene oxide or gamma radiation.

Results for non-sterile coupons are in Table 10.

Table 10

Sample	Coating (%/% heptdmac/silane)	Dip	Activity, mU/cm ²			
			unwashed 7 days	Unwashed 28 days	7 days wash	28 days wash
97-100-66A	2.0/2.0	Single	<125, <100	>10, >12	<10, <10	<2, <1
97-100-66E	2.0/2.0	Single	<100, <125	>10, >16	<10, <10	<1, 0

Results for ethylene oxide sterile coupons are in Table 11.

Table 11

Sample	Coating (%/% heptdmac/silane)	Dip	Activity, mU/cm ²			
			1 day unwashed	14 days unwashed	1 day	14 days
97-100-66A	2.0/2.0	Single	>12	>16, >16	<15	<2, <2
97-100-66E	2.0/2.0	Single	>12	>16, >16	<10	<3, <2

5

Results for gamma radiation sterilized coupons are in Table 12.

Table 12

Sample	Coating (%/% heptdmac/silane)	Dip	Activity, mU/cm ²					20 days
			1 day unwashed	14 days unwashed	20 days unwashed	1 day wash	14 days wash	
97-100-66A	2.0/2.0	Single	<200, <200	>16	>16	<20, <20	<1, <1	<1, <2
97-100-66E	2.0/2.0	Single	<200, <200	>16	>16	0,0	<2, <2	<2, <2

10

The resulting coatings were thin, with long term durability as evident by heparin activity results. Sterilization did not appear to affect coating properties, regardless of the sterilization mode.

Example 7:

15 Stainless steel coupons were dipped once, dipped twice, or dipped, washed, and then dipped again, at coating speeds of 10 in/min and for dwell times of two minutes, in the following formulations: 1) 0.5% heparin-TDMAC complex, 0.5% silane, 99% THF & small amount of Triton; 2) 0.5% heparin-TDMAC complex, 2.0% silane, 97.5% THF & small amount of Triton; 3) 2.0% heparin-TDMAC complex, 0.5% silane, 97.5% THF & small amount of Triton; and 4) 2.0% heparin-TDMAC complex, 2.0% silane, 96% THF & small
20 amount of Triton; and 4) 2.0% heparin-TDMAC complex, 2.0% silane, 96% THF & small

amount of Triton.

Heparin activity is shown in Table 13.

Table 13

Sample	Coating (%/% heptdmac/silane)	Dip	Activity, mU/cm ²						
			12 days unwashed	18 days unwashed	12 day wash	18 day wash	26 day wash	72 day wash	
5	97-100-69A	0.5/0.5	Single	>10	<175	0	<5	-	0
	97-100-69B	0.5/0.5	Double	>10	<150	<2	<2	-	<1
10	97-100-69C	0.5/0.5	Dip/wash/Dip	>10	<125	<2	<2	<1	<1
	97-100-69D	0.5/2.0	Single	<10	<75	<1	<5	-	<1
15	97-100-69E	0.5/2.0	Double	<5	<5	<1	<5	-	<1
	97-100-69F	0.5/2.0	Dip/wash/Dip	<2	<5	<2	<5	<2	<1
20	97-100-69G	2.0/0.5	Single	-	<15	-	<5	-	<1, <1
	97-100-69H	2.0/0.5	Double	-	<5	-	<5	-	<1, <1
25	97-100-69I	2.0/0.5	Dip/wash/Dip	-	<2	-	<5	<2, <2	0, <1
	97-100-69J	2.0/2.0	Single	-	<150	-	<5	-	<1, <1
30	97-100-69K	2.0/2.0	Double	-	<200	-	<5	-	<1, <1
	97-100-69K	2.0/2.0	Dip/wash/Dip	-	<250	-	<5	<3, <2	<1, <1

The resulting thin coatings demonstrated heparin activity, including light stains before and after rubbing. The long term durability of the coatings were evident through heparin activity results. Coating properties were variable according to different coating methods.

20 *Example 8:*

Stainless steel coupons were dipped twice, or were dipped, washed, and dipped again, at speeds of 10 in/min and for dwell times of two minutes, in the following formulations: 1) 0.5% heparin-TDMAC complex, 0.5% silane, 99% THF; and 2) 0.5% heparin-TDMAC complex, 2.0% silane, 97.5% THF. The pH of the coatings was adjusted

using acetic acid.

Heparin activity is shown in Table 14.

Table 14

Sample	Coating (%/% heptdmac/silane)	Dip	Activity, mU/cm ²		
			1 day unwashed	1 day	43 days
97-100-93A	0.5/0.5	Double	<75	<2	<2, <1
97-100-93B	0.5/0.5	Dip/wash/Dip	<50	<3	<1, <1
97-100-93C	0.5/2.0	Double	<50	<2	<2, <2
97-100-93D	0.5/2.0	Dip/wash/Dip	<1	<1	<2, <2

The resulting thin coatings demonstrated heparin activity, including light stains before and

after rubbing. The long term durability of the coatings was evident through heparin activity results. Coating properties were variable according to different coating methods.

Example 9:

Stainless steel coupons and stainless steel stents were dipped twice, or were dipped, washed with saline and distilled water, and dipped again, at coating speeds of 10 in/min and for dwell times of two minutes. Coating pH was adjusted using hydrochloric acid. Coatings derived from the following formulations were prepared: 1) 0.5% heparin-TDMAC complex, 0.5% silane, 99% THF; and 2) 0.5% heparin-TDMAC complex, 2.0% silane, 97.5% THF.

Heparin activity is shown in Table 15.

Table 15

Sample	Coating (% / % heptadmac/silane)	Dip	Activity, mU/cm ²					
			1 day unwashed	11 days unwashed	1 day washed	11 days wash	25 days wash	43 days wash
5	97-100-92A	0.5/0.5	Double	<25	<25, <25	<2	<1, <1	<1, <1, <5, <2, <2, <2
	97-100-92B	0.5/0.5	Dip/wash /Dip	<25	<10, <25	<2	<1, <1	<2, <2, <2, <2, <1, <2
	97-100-92D	0.5/2.0	Double	<10		<5	-	<5, <2 <1, <2
	97-100-92E	0.5/2.0	Dip/wash /Dip	<25		<2	-	<2, <2 <1 <1

Persistance of heparin activity after an increasing number of days suggests that most unattached heparin washes away immediately, but that attached heparin does not easily wash away even after prolonged exposure.

10 Activity on stents is disclosed in Table 16.

Table 16

Sample	Coating (% / % heptadmac/silane)	Dip	Activity, mU/cm ²	
			1 day unwashed	1 day
97-100-92C	0.5/0.5	Dip/wash/Dip	<125	<50
97-100-92F	0.5/2.0	Dip/wash/Dip	<50	<50

15 The resulting thin coatings showed light stains before and after rubbing. The coatings were durable as evident from heparin activity results. Coating properties were variable depending on different coating methods.

Example 10:

Stainless steel coupons and stainless steel stents were dipped, washed with IPA and

dipped again, at coating speeds of 10 in/min and for a dwell time of two minutes, in the following formulations: 1) 0.1% heparin-TDMAC complex, 0.5% silane, 99.4% THF; and 2) 0.2% heparin-TDMAC complex, 0.5% silane, 99.3% THF.

Heparin activity on coupons is shown in Table 17.

5

Table 17

Sample	Coating (% / % heptdmac/silane)	Dip	Activity, mU/cm ²		
			2 days unwashed	2 days wash	34 days wash
97-101-25A, Red	0.1/0.5	Double	<25	<1	<2
97-101-25A, Red	0.1/0.5	Double	<25	<1	<2
97-101-25B, green	0.1/0.5	Dip/wash/dip	<75	0	<2
97-101-25B, green	0.1/0.5	Dip/wash/dip	<50	0	<2
97-101-25C, yellow	0.2/0.5	Double	<50	<1	<5
97-101-25C, yellow	0.2/0.5	Double	<25	<1	<5
97-101-25D, brown	0.2/0.5	Dip/wash/dip	<50	<1	<2
97-101-25D, brown	0.2/0.5	Dip/wash/dip	<25	<1	<2

10

Hepain activity on stents is shown in Table 18

15

Table 18

Sample	Coating (% / % heptdmac/silane)	Dip	Activity, mU/cm ²		
			2 days unwashed	2 days wash	16 days wash
97-101-25A, Red	0.1/0.5	Double	<225	<5	<2
97-101-25A, Red	0.1/0.5	Double	<225	0	<3
97-101-25B, green	0.1/0.5	Dip/wash/dip	<125	<1	<2
97-101-25B, green	0.1/0.5	Dip/wash/dip	<100	0	<5
97-101-25C, yellow	0.2/0.5	Double	<200	<15	<3
97-101-25C, yellow	0.2/0.5	Double	<100	<5	<10
97-101-25D, brown	0.2/0.5	Dip/wash/dip	<200	<5	<10
97-101-25D, brown	0.2/0.5	Dip/wash/dip	<225	<10	<5

20

25

The resulting thin coatings showed light stains before and after rubbing. The coatings were durable as evident from heparin activity results. Coating properties were variable depending on different coating methods.

Example 11:

Stainless steel stents were dipped once, at coating speeds of 10 in/min and for dwell times of five seconds and two minutes, in the following formulations: 1) 4.0% heparin-TDMAC complex, 8.0% silane, 88% THF, small amount of Triton; 2) 4.0% heparin-TDMAC complex, 4.0% silane, 92% THF, small amount of Triton; and 3) 2.0% heparin-TDMAC complex, 2.0% silane, 96% THF, small amount of Triton.

Heparin activity is shown in Table 19.

Table 19

Sample	Coating (% / % heptdmac/silane)	Dip	Activity, mU/cm ²	
			Unwashed	3/4 days
97-100-50A	4/8	Single	<175	<50
97-101-50B	4/4	Single	<150	<125
97-100-54B	2/2	Single	<225	<25 (4 days)

Again, coating properties varied using different coating methods.

Example 12:

Stainless steel stents were dipped twice, at coating speeds of 10 in/min and at a dwell time of two minutes, in the following formulations: 1) 0.2% heparin-TDMAC complex, 0.5% silane; 2) 0.5% heparin-TDMAC complex, 0.5% silane; 3) 0.5% heparin-TDMAC complex, 1.0% silane; 4) 1.0% heparin-TDMAC complex, 1.0% silane; and 5) 1.0% heparin-TDMAC complex, 2.0% silane. Stents were either left unsterilized or were sterilized with gamma radiation.

Table 20 shows results for non-sterile stents.

Table 20

Sample #	Coating (% / % heptdmac/silane)	Dip	Activity, mU/cm ²	
			4 days unwashed	4 days
97-101-86A	0.2/0.5	Double	<100	<1
	0.2/0.5	Double	<125	<1
97-101-86B	1.0/2.0	Double	<200	<10
	1.0/2.0	Double	<225	<5
97-101-86C	1.0/1.0	Double	<225	<5
	1.0/1.0	Double	<225	<5
97-101-86D	0.5/1.0	Double	<200	<5
	0.5/1.0	Double	<225	<5
97-101-86E	0.5/0.5	Double	<225	<5
	0.5/0.5	Double	<200	<5
97-101-86F	0.5/1.0 Sutton	Double	<125	<1
	0.5/1.0 Sutton	Double	<125	<5

Table 21 shows activity for sterile stents.

Table 21

Sample #	Coating (% / % heptdmac/silane)	Dip	Activity, mU/cm ²	
			4 days unwashed	4 days
97-101-86A	0.2/0.5	Double	>200	<1
	0.2/0.5	Double	>200	<5
97-101-86B	1.0/2.0	Double	>200	<10
	1.0/2.0	Double	>200	<5
97-101-86C	1.0/1.0	Double	>200	<10
	1.0/1.0	Double	>200	<10
97-101-86D	0.5/1.0	Double	>200	<5
	0.5/1.0	Double	>200	<5
97-101-86E	0.5/0.5	Double	>200	<5
	0.5/0.5	Double	>200	<5
97-101-86F	0.5/1.0 Sutton	Double	>200	<5
	0.5/1.0 Sutton	Double	>200	<5

Sterilization showed no effect on coating properties. The coatings were durable on stents, as evident by heparin activity after several days of washing.

Example 13:

Several coupons and stents were coated with 0.2% heparin-TDMAC complex, 0.5% silane and 99.3% THF. These pieces were sterilized by gamma radiation and sent to NAMSA for biocompatibility testing. Three tests, Hemolysis, Cytotoxicity and 5 Thromboresistance, were conducted. The coating passed all three tests.

In addition to the foregoing examples, various other methods and coatings may be envisioned in the spirit of the present disclosure. For example, heparin might be covalently linked to a substrate with a silane identified as capable of being soaked into a stainless steel surface. The silane compound could have amino or epoxy terminal groups. The silane could thus be used to link heparin molecules to the substrate in a manner similar to the silane of 10 isocyanate functionality disclosed herein. Heparin could then be prepared with an aldehyde positive group that mixed with an NH₂ group to provide an end linkable to heparin without affecting its activity. The procedure to make degraded heparin is well known to those of ordinary skill in the art.

15 A coating system may also be provided in which heparin can be covalently linked or can be incorporated into a matrix to obtain variable rate of elution. A silicon fluid, such as Dow Corning MDX 4-4159 is used, with the active silicon being an amino functional polydimethyl siloxane copolymer. The coating may be used to coat stainless steel guide wires. This working can be utilized for heparin covalent-bonding as described below.

20 First, a solution of heparin (deaminated) in water or other solvent may be provided. A

wire coated with a silicon fluid in a solvent may be placed in the solution for some time, for example two hours. The heparin has an aldehyde group that can link to the amino functionality in the silicon copolymer. Other amino functionalized silicon polymers, or copolymers, can be used to achieve covalent bonding of heparin to the substrate.

5 Equivalents

While the invention has been disclosed in connection with the preferred embodiments shown and described in detail, various modifications and improvements thereon will become readily apparent to those skilled in the art. Accordingly, the spirit and scope of the present invention is to be limited only by the following claims.

We Claim:

1. A coating, comprising:
 - a silane; and
 - a biopolymer, wherein said biopolymer is covalently linked to the silane.
2. The coating of claim 1, wherein the silane has functionality capable of reacting with a hydroxyl group.
3. The coating of claim 1, wherein the silane comprises at least one of isocyanate, isothiocyanate, ester, anhydride, acyl halide, alkyl halide, epoxide, or aziridine functionality.
4. The coating of claim 1, wherein the silane comprises isocyanate functionality.
5. The coating of claim 4, wherein the biopolymer is derived from heparin-tridodecylmethylammonium chloride.
6. The coating of claim 1, wherein the biopolymer is derived from a complex selected from the group consisting of heparin-tridodecylmethylammonium chloride, heparin-benzalkonium chloride, heparin-steralkonium chloride, heparin-poly-*N*-vinyl-pyrrolidone, heparin-lecithin, heparin-didodecyldimethylammonium bromide, heparin-pyridinium chloride, and heparin-synthetic glycolipid complex.

7. The coating of claim 1, wherein the biopolymer has hydroxyl or amine functional groups that can react with isocyanate functionality.
8. The coating of claim 1, wherein the biopolymer comprises an adduct of heparin molecules.
9. The coating of claim 7, wherein the heparin is provided in a form capable of dissolving in an organic solvent.
10. The coating of claim 1, wherein the biopolymer provides thromboresistance.
11. The coating of claim 1, wherein the biopolymer is derived from heparin-tridodecylmethylammonium chloride.
12. The coating of claim 1, further comprising at least one of a wetting agent and an additive.
13. The coating of claim 1, wherein the silane has an organic chain between isocyanate and silane functional groups.
14. A coating for a medical device, wherein thromboresistance activity can be modified, comprising:
heparin-tridodecylmethylammonium chloride;

a silane having isocyanate functionality; and
an organic solvent.

15. The coating of claim 14, wherein the quantity of at least one of the silane and the heparin-tridodecylmethylammonium chloride complex is selected to provide desired thromboresistance.
16. The coating of claim 15, wherein the concentration of the silane is between about one-tenth percent and about twenty percent.
17. The coating of claim 15, wherein the concentration of the silane is between about one-tenth percent and about ten percent.
18. The coating of claim 15, wherein the concentration of the silane is between about one-tenth percent and about five percent.
19. The coating of claim 15, wherein the concentration of the silane is between about one-half percent and about four percent.
20. The coating of claim 15, wherein the concentration of heparintridodecylmethylammonium chloride is between about one-tenth percent and about twenty percent.
21. The coating of claim 15, wherein the concentration of heparintridodecylmethyl-

ammonium chloride is between about one-tenth percent and about ten percent.

22. The coating of claim 15, wherein the concentration of heparin-tridodecylmethylammonium chloride is between about one-tenth percent and about five percent.
23. The coating of claim 15, wherein the concentration of heparin-tridodecylmethylammonium chloride is between about one-tenth percent and about four percent.
24. The coating of claim 15, wherein the concentration, of the silane is about five-tenths percent and the concentration of the heparin-tridodecylmethylammonium chloride is about two-tenths percent.
25. The coating of claim 14, wherein the organic solvent tetrahydrofuran is used to prepare the solution applied to the surface.
26. The coating of claim 14, wherein the silane and the heparin-tridodecylmethylammonium chloride are provided in a single layer.
27. The coating of claim 14, further comprising a surface active agent.
28. The coating of claim 27, wherein the surface active agent is Triton.

29. A coated medical device, comprising:

 a substrate; and

 a coating derived from heparin-tridodecylmethylammonium chloride, a silane having isocyanate functionality, and an organic solvent.

30. The coated medical device of claim 29, wherein the solution applied to the surface comprises silane and heparin-tridodecylmethylammonium chloride, and said solution is applied directly to the substrate without the use of a primer.

31. The medical device of claim 29, wherein the silane and the heparin-tridodecylmethylammonium chloride are applied in a single layer.

32. The device of claim 29, wherein the heparin is covalently bonded to the substrate.

33. The device of claim 29, wherein the device is a stent.

34. The device of claim 33, wherein the stent is made of at least one of stainless steel, nitinol, tantalum, glass, ceramic, nickel, titanium and aluminum.

35. A method of coating a medical device, comprising covalently bonding a heparin to the medical device.

36. The method of claim 35, further comprising:
applying a silane having functionality capable of reacting with a hydroxyl group to the medical device.

37. The method of claim 36, wherein the silane has isocyanate functionality.

38. The method of claim 35, wherein the heparin is derived from heparin-tridodecylmethylammonium chloride.

39. The method of claim 36, further comprising:
dissolving heparin-tridodecylmethylammonium chloride and the silane in an organic solvent prior to applying the solution to the substrate.

40. The method of claim 39, wherein the organic solvent is tetrahydrofuran.

41. The method of claim 36, further comprising:
applying the heparin-tridodecylmethylammonium chloride and the silane to the medical device in a single layer.

42. The method of claim 36, further comprising:
adjusting the concentration, in the solution applied to the surface, of at least one of the silane and the heparin-tridodecylmethylammonium chloride to provide desired thromboresistance.

43. The method of claim 42, wherein the concentration of the silane is between about one-tenth percent and about twenty percent.

44. The method of claim 42, wherein the concentration of the silane is between about one-tenth percent and about ten percent.

45. The method of claim 42, wherein the concentration of the silane is between about one-tenth percent and about five percent.

46. The method of claim 42, wherein the concentration of the silane is between about one-half percent and about four percent.

47. The method of claim 42, wherein the concentration of heparintridodecylmethylammonium chloride is between about one-tenth percent and about twenty percent.

48. The method of claim 42, wherein the concentration of heparintridodecylmethylammonium chloride is between about one-tenth percent and about ten percent.

49. The method of claim 42, wherein the concentration of heparintridodecylmethylammonium chloride is between about one-tenth percent and about five percent.

50. The method of claim 42, wherein the concentration of heparintridodecylmethylammonium chloride is between about one-tenth percent and about four percent.

51. The method of claim 42, wherein the concentration, of the silane is about five-tenths percent and the concentration of the heparin-tridodecylmethylammonium chloride is about two-tenths percent.

52. The method of claim 36, further comprising:
oxidizing the medical device prior to applying the silane and the heparin-tridodecylmethylammonium chloride.

53. A method of coating a medical device, comprising:
dissolving heparin-tridodecylmethylammonium chloride and a silane having isocyanate functionality in an organic solvent; and applying said solution to the device to form a coating on the medical device.

54. The method of claim 53, further comprising:
oxidizing a surface of the medical device prior to applying the coating.

55. The method of claim 53, further comprising:
providing a wetting agent in conjunction with applying the coating.

56. The method of claim 53, further comprising:
adding a film-forming agent to the coating.

57. The method of claim 56, wherein the film forming agent is selected from the group consisting of cellulose esters, polydialkyl siloxanes, polyurethanes, acrylic polymers, elastomers, biodegradable polymers, polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid and poly(e-caprolactone).

58. The method of claim 53, further comprising:
adding a non-functional silane to the coating.

59. The method of claim 58, wherein the non-functional silanes are selected from the group consisting of chain alkyltrialkoxysilanes and phenyltrialkoxysilanes.

Abstract of the Disclosure

Coatings are provided in which biopolymers may be covalently linked to a substrate. Such biopolymers include those that impart thromboresistance and/or biocompatibility to the substrate, which may be a medical device. Coatings disclosed herein include those that permit coating of a medical device in a single layer, including coatings that permit applying the single layer without a primer. Suitable biopolymers include heparin complexes, and linkage may be provided by a silane having isocyanate functionality.

DECLARATION FOR PATENT APPLICATION

Docket Number BAK-073.01

As a below named inventor, I/we hereby declare that:

My/our residence, post office address(es) and citizenship(s) are as stated below next to my/our name.

I/we believe I/we am/are the original, first and sole inventor(s) (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: THROMBORESISTANT COATING
the specification of which (check one)

(X) is attached hereto.

() was filed on _____ as United States Application Number or PCT International Application

Number _____, and was amended on _____ (if applicable).

I/we hereby state that I/we have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I/we acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulation, § 1.56.

I/we hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Claimed
 () Yes () No

(Number)	(Country)	(Day/Month/Year Filed)
<input type="text"/>	<input type="text"/>	<input type="checkbox"/> () Yes <input type="checkbox"/> () No

(Number)	(Country)	(Day/Month/Year Filed)
<input type="text"/>	<input type="text"/>	<input type="checkbox"/> () Yes <input type="checkbox"/> () No

I/we hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States Provisional application(s) listed below.

(Application Number)	(Filing Date)	
<input type="text"/>	<input type="text"/>	<input type="checkbox"/> () Yes <input type="checkbox"/> () No

(Application Number)	(Filing Date)	
<input type="text"/>	<input type="text"/>	<input type="checkbox"/> () Yes <input type="checkbox"/> () No

I/we hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I/we acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)
<input type="text"/>	<input type="text"/>	<input type="checkbox"/> () Yes <input type="checkbox"/> () No


I/we hereby appoint Beth E. Arnold, Reg. No. 35,430; Paula A. Campbell, Reg. No. 32,503; Charles H. Cella, Reg. No. 38,099; Edward J. Kelly, Reg. No. 38,936; Donald W. Muirhead, Reg. No. 33,978; Chinh H. Pham, Reg. No. 39,329; and Matthew P. Vincent, Reg. No. 36,709 as attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Address all telephone calls to Charles H. Cella at telephone number (617) 832-1187.

Address all correspondence to: Patent Group
Foley, Hoag & Eliot LLP
One Post Office Square
Boston, Ma. 02109-2170

I/we hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor (given name, family name) Chirag B. Shah

Inventor's signature 


Date August 18, 1998

Residence 28 New Castle Dr., #11, Nashua, NH 03060

Citizenship INDIA

Post Office Address 28 New Castle Dr., #11, Nashua, NH 03060

Full name of second joint inventor, if any (given name, family name) Laurel L Wolfgang

Inventor's signature 

Date August 18, 1998

Residence 1 Peach Lane, Townsend, MA 01469

Citizenship USA

Post Office Address 1 Peach Lane, Townsend, MA 01469

Additional inventors are being named on separately numbered sheets attached hereto.